Safety and Efficacy for Koreans Proven Through Large-Scale Clinical Trials
Daewoong Pharmaceutical is accelerating its market expansion for Violette, a fat-dissolving injection, leveraging its proven safety and efficacy as well as features optimized for recent beauty trends.
Yoon Junsu, Head of Nabota Business Division at Daewoong Pharmaceutical, is introducing deoxycholic acid (DCA), the main ingredient of the fat-dissolving injection Violette, at a press conference held on the 15th in Gangnam-gu, Seoul. Daewoong Pharmaceutical
On July 15, Daewoong Pharmaceutical held a press conference at Chosun Palace in Gangnam-gu, Seoul, to highlight the advantages and vision of Violette and to present the latest research findings related to its main ingredient, deoxycholic acid (DCA).
Violette is the first domestically produced fat-dissolving injection launched by Daewoong Pharmaceutical in 2021. It is the only product in the industry whose safety and efficacy have been verified through four large-scale clinical studies involving approximately 960 Koreans. Yoon Junsu, Head of the Nabota Business Division at Daewoong Pharmaceutical, stated, "Violette is stably supplied to more than 2,000 hospitals and clinics nationwide and is recognized for its clinical value. It is the only fat-dissolving injection whose efficacy and effects have been thoroughly validated for Koreans through phase 3 clinical trials and post-marketing surveillance in Korea."
Recent beauty trends are shifting toward "micro beauty," which focuses on contouring localized areas such as under the chin, upper arms, and thighs. As non-surgical procedures with quick recovery attract attention, the rising popularity of GLP-1 class treatments for obesity and weight loss is also driving increased demand for complementary procedures to address issues like skin laxity or residual localized fat.
Park Jeyoung, Director of Apgujeong Oracle Dermatology Clinic, who introduced beauty market trends and the potential of DCA, explained, "DCA directly targets and destroys fat cells in the desired area, providing semi-permanent effects, which aligns well with recent aesthetic trends. The procedure can be completed in just 10 to 20 minutes, and patients can quickly return to daily life, so I expect it to become a major item driving the aesthetic market in the future."
Currently, DCA is approved in Korea for the improvement of moderate to severe protruding or excessive submental fat in adults. However, overseas, clinical experience and research results have already been reported for various areas, including the upper arms, cheeks, under the eyes, armpits, flanks, and thighs. In addition, research is underway on its use for conditions such as lipomas and turkey neck syndrome, so further expansion into various treatment areas and purposes is anticipated in the future.
The final session of the day featured the first-ever presentation in Korea of a study on the effect of DCA on the reduction of subcutaneous fat in the upper arms (posterior upper arm) of Korean subjects. According to this clinical study, which involved Yoon Chunsik, Director of Yemione Dermatology Clinic, and Park Guyoung, Professor at Chung-Ang University Hospital, a reduction in subcutaneous fat thickness was observed at all dosages after three DCA treatments and 20 weeks of follow-up.
This study not only confirmed for the first time the potential of DCA for upper arm fat reduction in Koreans, but also drew attention by presenting a dilution technique that delivers efficacy while improving patient compliance and cost-effectiveness.
Daewoong Pharmaceutical plans to continue promoting Violette's unique strengths through ongoing research and marketing activities, while expanding its indications and actively targeting the market to develop Violette into a blockbuster product.
Park Sungsoo, CEO of Daewoong Pharmaceutical, stated, "Violette not only aligns with recent beauty trends but also has the potential for expansion into various fields. We will continue to listen to market changes and customer feedback, while maintaining our commitment to ongoing research, development, and investment."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
